Gastrointestinal and Hepatobiliary Immune-related Adverse Events : A Histopathologic Review
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
Immune checkpoint inhibitors have been increasingly used to treat various malignant neoplasms. Despite their superior efficacy in treating certain ones, their global immune-activation effect leads to systemic side effects, referred to as immune-related adverse events. Immune-related adverse events affect a variety of organs, including the skin, gastrointestinal, hepatobiliary, and endocrine organs. Gastrointestinal tract immune-related adverse events present with a wide range of symptoms with variable severity, which may lead to treatment interruption and administration of immunosuppression therapy in many cases. Histopathologic changes are diverse, overlapping with many other conditions. Therefore, recognizing these changes is crucial in diagnosing immune-related adverse events. This review discusses the pathologic manifestations of gastrointestinal immune-related adverse events and discusses the primary differential diagnoses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Advances in anatomic pathology - 30(2023), 3 vom: 01. Mai, Seite 230-240 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alruwaii, Zainab I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 12.04.2023 Date Revised 12.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/PAP.0000000000000401 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355420104 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355420104 | ||
| 003 | DE-627 | ||
| 005 | 20231226064316.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/PAP.0000000000000401 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355420104 | ||
| 035 | |a (NLM)37037419 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alruwaii, Zainab I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gastrointestinal and Hepatobiliary Immune-related Adverse Events |b A Histopathologic Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2023 | ||
| 500 | |a Date Revised 12.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a Immune checkpoint inhibitors have been increasingly used to treat various malignant neoplasms. Despite their superior efficacy in treating certain ones, their global immune-activation effect leads to systemic side effects, referred to as immune-related adverse events. Immune-related adverse events affect a variety of organs, including the skin, gastrointestinal, hepatobiliary, and endocrine organs. Gastrointestinal tract immune-related adverse events present with a wide range of symptoms with variable severity, which may lead to treatment interruption and administration of immunosuppression therapy in many cases. Histopathologic changes are diverse, overlapping with many other conditions. Therefore, recognizing these changes is crucial in diagnosing immune-related adverse events. This review discusses the pathologic manifestations of gastrointestinal immune-related adverse events and discusses the primary differential diagnoses | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Montgomery, Elizabeth A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in anatomic pathology |d 1997 |g 30(2023), 3 vom: 01. Mai, Seite 230-240 |w (DE-627)NLM093789904 |x 1533-4031 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2023 |g number:3 |g day:01 |g month:05 |g pages:230-240 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/PAP.0000000000000401 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2023 |e 3 |b 01 |c 05 |h 230-240 | ||